Document Detail


Decreased expression of LMO7 and its clinicopathological significance in human lung adenocarcinoma.
MedLine Citation:
PMID:  22977619     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
LIM-domain only protein 7 (LMO7) has been suggested to act as a tumor suppressor for murine lung adenocarcinoma, while its splice variant p100 LMO7/#16 is associated with invasion and metastasis of rat AH130W1 cells. However, the importance of LMO7 in human lung cancer is unknown. We investigated LMO7 protein expression by immunohistochemistry in tumor tissues obtained from 57 patients with adenocarcinoma of the lung using a rabbit anti-LMO7 antibody. Signals for LMO7 were localized to the apical surface of the bronchial epithelium and to the cell membranes of pneumocytes in non-cancerous pulmonary tissues, but were noted circumferentially around the plasma membrane of cancer cells in all 57 patients with adenocarcinoma. The LMO7-positive group (24 patients, 42%) showed equivocal to strong expression of LMO7 in more than 50% cancer cells, while the remaining 33 patients (58%) showed LMO7 expression in less than 50% of their cancer cells. The latter group had significantly more advanced disease than the LMO7-positive group with regard to T factor (p=0.011), nodal involvement (p=0.026) and p-stage (p=0.010; χ(2) test). Multivariate analysis using a logistic regression model showed that LMO7 expression was independently associated with the T factor (p=0.041). Kaplan-Meier analysis showed that a poor prognosis was associated with low expression of LMO7 (p=0.036; log-rank test). Our findings are consistent with earlier observations and demonstrate that LMO7 is inversely correlated with the development and prognosis of human lung adenocarcinoma.
Authors:
Hiroyuki Nakamura; Keiko Hori; Miki Tanaka-Okamoto; Masahiko Higashiyama; Yu Itoh; Masahiro Inoue; Setsuko Morinaka; Jun Miyoshi
Related Documents :
23023419 - Effect of bisphosphonates on anticancer activity in prostate cancer cells.
22923609 - Meprinα transactivates the epidermal growth factor receptor (egfr) via ligand shedding...
23586879 - Antimitotic agents for the treatment of patients with metastatic castrate-resistant pro...
23852449 - Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting ptgs2 (c...
16077929 - Increased level of the p67phox subunit of nadph oxidase by 4hpr in head and neck squamo...
24536059 - Molecular pathways: emerging roles of mammalian sirtuin sirt7 in cancer.
4068799 - Fat intake, obesity, and cancer of the breast and endometrium.
17558909 - Protein thiols and thiobarbituric acid reactive substance status in colon cancer patients.
18366039 - Herceptin-platinum(ii) binding complexes: novel cancer-cell-specific agents.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-11
Journal Detail:
Title:  Experimental and therapeutic medicine     Volume:  2     ISSN:  1792-1015     ISO Abbreviation:  Exp Ther Med     Publication Date:  2011 11 
Date Detail:
Created Date:  2012-9-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101531947     Medline TA:  Exp Ther Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1053-1057     Citation Subset:  -    
Affiliation:
Departments of Biochemistry.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcin...
Next Document:  Long-term survival results and prognostic factors of early gastric cancer.